Journal
AMERICAN JOURNAL OF PATHOLOGY
Volume 189, Issue 10, Pages 2090-2101Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2019.06.007
Keywords
-
Categories
Funding
- Scott & White Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology, a Veterans Affairs Research Career Scientist Award
- Central Texas Veterans Health Care System
- Italian Foundation of Cancer Research awards [MFGA17588, IG17786]
- ArQule, Inc.
Ask authors/readers for more resources
Fibroblast growth factor receptor 2 (FGFR2) might have an important role in the pathogenesis and biology of cholangiocarcinoma (CCA). We examined FGFR expression in CCA tumor specimens obtained from patients and CCA cell lines, and then determined the effects of the novel. FGFR inhibitor, derazantinib (DZB; formally, ARQ 087), which is currently in clinical phase 2 trials for intrahepatic CCA. DZB inhibited the growth of CCA cell lines in a dose-dependent manner, and extracellular signal-regulated kinase 1/2 and AKT. It also activated apoptotic and cell growth arrest signaling. DZB reduced the in vitro invasiveness and the expression of key epithelial-mesenchymal transition genes. The in vitro data correlated with the expression of FGFRs in human CCA specimens by immunohistochemistry (FGFR1, 30% positive; and FGFR2, 65% positive) and the CCA cell lines assayed by Western blot analysis. These correlated in vitro studies suggest that FGFR may play an important role in the pathogenesis and biology of CCA. Our findings support the notion that FGFR inhibitors, like DZB, should be further evaluated at the clinical stage as targeted therapy for CCA treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available